EGFR Wildtype

CI-VAR-00004729Explore in graph →CIViC 2174

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR Wildtype	Gefitinib	Predictive	B	Does Not Support Reduced Sensitivity	3	rejected	EID6185 In a Japanese Phase III trial, noninferiority of gefitinib in comparison to erlotinib was assessed in lung adenocarcinoma patients with postoperative or recurrent stage IIIb/IV lung adenocarcinoma tre… (full text at CIViC) PMID 27022112 · Urata et al., 2016 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma2
EGFR Wildtype	Deguelin	Predictive	D	Supports Sensitivity Response	3	submitted	EID12204 Deguelin inhibits EGFR signaling in wild-type NSCLC cells. It reduces EGFR phosphorylation and downstream signalling, as shown by decreased phosphorylation of Akt and ERK1/2. This effect was not obser… (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.